RxDoctor Payments Data

Gregory Bruce, MD

Clinical Cardiac Electrophysiology · Chattanooga, TNNPI 1306814520

Payments from drug & device makers

$2,874in general payments, 2019–2025

Across 79 payments — averaging $36.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$594
  • Medtronic$493
  • Atricure, Inc.$399
  • Irhythm Technologies, Inc.$309
  • Biosense Webster, Inc.$269
  • Medical Device Business Services, Inc.$232
  • plus $577 from 8 others

What the payments were for

  • Consulting fees$1585%
  • Travel & lodging$33612%
  • Food & beverage$2,38083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,874 in reported general payments places this provider in the 20th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

See all clinical cardiac electrophysiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$429,109
Medicare patients
1,628
Services billed
7,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban761$880,487
XareltoRivaroxaban243$284,815
MultaqDronedarone Hcl55$64,493
Flecainide Acetate438$22,708
EntrestoSacubitril/Valsartan18$19,778
Dabigatran EtexilateDabigatran Etexilate Mesylate42$9,159
Metoprolol Succinate361$7,250
Mexiletine Hcl39$7,109
CorlanorIvabradine Hcl12$7,027
Diltiazem 24hr Er (Cd)Diltiazem Hcl129$5,684
Propafenone Hcl58$4,456
SotalolSotalol Hcl196$4,401
Dofetilide21$3,694
Amiodarone Hcl171$3,673
Propafenone Hcl ErPropafenone Hcl11$3,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$880,487761 claims
NovartisEntresto$122$19,77818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

Other clinical cardiac electrophysiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →